Sonoma Pharmaceuticals, Inc. reported a significant increase in revenue for the second quarter of fiscal year 2026, with total revenues reaching $5.6 million, up 57% from $3.6 million in the same period last year. For the six months ending September 30, 2025, revenues totaled $9.6 million, a 38% increase compared to $7.0 million for the same period in 2024. The company attributed this growth primarily to increased sales in human health care products and over-the-counter animal health care products, particularly in the United States and Europe.
Despite the revenue growth, Sonoma Pharmaceuticals reported a net loss of $534,000 for the three months ended September 30, 2025, a slight improvement from a net loss of $610,000 in the prior year. For the six-month period, the net loss was $1.8 million, compared to $1.8 million in the same period last year. The company’s accumulated deficit increased to $199.6 million as of September 30, 2025, from $197.8 million at the end of the previous fiscal year. The loss per share improved to $(0.32) from $(0.59) year-over-year for the quarter, reflecting a reduction in losses relative to the number of shares outstanding.
Operationally, Sonoma Pharmaceuticals has made strides in expanding its product offerings and market reach. The company relaunched several dermatology products in the U.S. market in December 2024 and has entered into a Master Supply Agreement with WellSpring Pharmaceutical Corporation for the sale of its Microcyn technology-based products. Additionally, the company has expanded its product line in the wound care segment and is actively pursuing new applications for its hypochlorous acid technology. As of September 30, 2025, the company had 1,649,765 shares outstanding, an increase from 1,634,265 shares at the end of the previous quarter.
The company’s cash and cash equivalents decreased to $3.0 million from $5.4 million at the end of the previous fiscal period, primarily due to net cash used in operating activities of $2.7 million. Sonoma Pharmaceuticals reported working capital of $8.2 million, down from $8.6 million in March 2025. The company continues to explore additional capital resources through equity offerings and collaborations, although it acknowledged the uncertainty surrounding its ability to secure financing under potentially favorable terms. Management expressed concerns regarding the company's ability to continue as a going concern if it cannot secure additional capital, given its history of operating losses.
Looking ahead, Sonoma Pharmaceuticals remains focused on expanding its product lines and market presence, particularly in the dermatology and wound care sectors. The company is also monitoring global economic conditions and potential impacts on its operations, including foreign currency fluctuations and tax liabilities. The management team is committed to enhancing operational efficiencies and driving revenue growth to achieve profitability in the future.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals specializes in developing and manufacturing stabilized hypochlorous acid (HOCl) products for healthcare and disinfection. Its core segments include wound care, dermatology, eye, oral, nasal, podiatry, animal health, and surface disinfectants. The company markets globally through direct sales and partnerships, emphasizing safe, effective, and cost-efficient solutions backed by extensive regulatory approvals and proprietary technology.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.